Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s First Genetic Engineering Pharmaceutical Base To Begin Operations in 2010

This article was originally published in PharmAsia News

Executive Summary

China's first national genetic engineering pharmaceutical base will begin operating next year in Changchun city, in northeastern China. Covering 45,000 square meters, the RMB 330 million base, funded by GeneScience Pharmaceuticals, will produce more than 10 types of patented products including genetically engineered thymosin, long-acting growth hormone and follicle-stimulating hormone. The facility's revenue is expected to reach RMB 2 billion within five years after its launch, and to climb to RMB 5 billion within eight years. While adopting advanced international standards, the facility is set to boost China's biopharmaceutical industry. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071127

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel